Inventiva S.A. (IVA)
About Inventiva S.A.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $842.1M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $842.1M
- Shares outstanding
- 188.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 10, 2020
Inventiva S.A. (IVA) Stock Price
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inventiva S.A..
Write a review
News about Inventiva S.A.
News & sentiment via Polygon.io
Inventiva S.A.: frequently asked questions
Is Inventiva S.A. an American company?
Inventiva S.A. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Inventiva S.A. publicly traded?
Yes — Inventiva S.A. is a publicly traded company. Its stock trades under the ticker symbol IVA on the NASDAQ.
What does Inventiva S.A. do?
Inventiva S.A. is an American Pharmaceuticals company in the Health & Beauty sector.
